Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 23.0%
Concerns1
- Low return on equity of 8.3%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 7 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ4.38 K Cr | β | βΉ317.00 Cr | β | β | 10.5% | 25.3% | 96.9% |
| Mar 2024 | βΉ3.50 K Cr | β | βΉ161.00 Cr | β | β | 8.3% | 12.6% | 0.6% |
| Mar 2023 | βΉ3.11 K Cr | β | βΉ160.00 Cr | β | β | 8.7% | -8.3% | -64.2% |
| Mar 2022 | βΉ3.39 K Cr | β | βΉ447.00 Cr | β | β | 26.1% | 7.4% | 6.4% |
| Mar 2021 | βΉ3.15 K Cr | β | βΉ420.00 Cr | β | β | 18.2% | 32.7% | 140.0% |
| Mar 2020 | βΉ2.38 K Cr | β | βΉ175.00 Cr | β | β | 9.1% | -3.2% | -38.4% |
| Mar 2019 | βΉ2.45 K Cr | β | βΉ284.00 Cr | β | β | 16.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 4,664 |
| Total Expenses | 3,850 |
| EBIT / Operating Profit | 815 |
| OPM % | 17% |
| Other Income | 90 |
| Finance Costs | 92 |
| Depreciation & Amortisation | 235 |
| Profit Before Tax | 577 |
| Tax % | - |
| Net Profit / PAT | 430 |
| EPS (βΉ) | 22.70 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Limitedthis co. | βΉ29.40 K Cr | βΉ4.38 K Cr | 67.90 | 9.12 | 53.49 | 25.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |